Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady 
Instagram Outage Disrupts Thousands of U.S. Users 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Oil Prices Slip as U.S.–Iran Talks Ease Supply Disruption Fears 
Medtronic plc, a leading global healthcare technology company headquartered in Dublin, Ireland, is set to acquire EOFlow, a wearable insulin patch maker based in South Korea, for $738 million.
The Korea Economic Daily reported that Medtronic confirmed it has signed a share purchase agreement (SPA) to buy all the shares of EOFlow's chief executive officer Jesse Kim and president Luis Malave. The medical device company said that their shares are priced at KRW30,000 per share or about $22.60.
The price is said to be higher 19.8% higher compared to the KRW25,050 closing stock price on Friday, May 26. This is also said to be EOFlow's highest share price since November 2021, and the surge was hinted to be due to Medtronic's acquisition plan of the company.
EOFlow said that its CEO Jesse Kim currently owns the biggest stake in the company, and he signed a SPA with Medtronic Korea Holdings for the sale of the 18.58% stake, which he owns for KRW169.2 billion. On the other hand, EOFlow's president Luis Malave holds less than five percent of the company.
"Our goal is to simplify diabetes management and deliver the well-established benefits of automated insulin delivery to our customers in the ways they want and need," Medtronic Diabetes' executive vice president and president, Que Dallara, said in a press release. "We are excited to introduce a differentiated wearable patch option to provide more patient choice and drive further innovation for those who want to use technology to make living with diabetes easier."
EOFlow's founder and CEO, Jesse Kim, added, "We are thrilled to accelerate our next phase of growth with a partner like Medtronic who shares our goal of simplifying diabetes management to make life easier for the customers we serve."
Meanwhile, JP Morgan Securities LLC has been assigned by Medtronic as its financial advisor for the transaction, while Kim & Chang and Ropes & Gray LLP serve as its legal advisors. For EOFlow, it has hired Goldman Sachs & Co. LLC as its financial advisor and Bae, Kim & Lee LLC acting as its legal advisor.
Photo by Tony Webster/Flickr(CC BY 2.0)
